Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Target enrollment exceeded with 1009 patients randomized in the main cohort and 410…
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
March 03, 2025 09:27 ET | Source: Pliant Therapeutics, Inc. SOUTH SAN…
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trialin Patients with Idiopathic Pulmonary Fibrosis
February 07, 2025 16:58 ET | Source: Pliant Therapeutics, Inc. Following DSMB…